MedTrace Logo

Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer

NCT07637786 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-06-10

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and preliminary effectiveness of a new combination therapy in patients with advanced pancreatic cancer.

The main questions it aims to answer are:

1. Is the combination of the peptide nanovaccine (ONVAX-01), an anti-PD-1 antibody, and chemotherapy safe and well-tolerated?
2. Does this combination treatment help shrink tumors or stop the progression of advanced pancreatic cancer?

Participants will be asked to:

1. Receive doses of the peptide nanovaccine (ONVAX-01).
2. Receive intravenous infusions of an anti-PD-1 antibody and standard chemotherapy.
3. Undergo regular physical exams, blood tests, and imaging scans (such as CT or MRI) to monitor their health and the tumor's response to the treatment.

Conditions

  • Advanced Pancreatic Adenocarcinoma

Interventions

DRUG

ONVAX-01 plus Anti-PD-1 and Chemotherapy

The peptide nanovaccine (ONVAX-01) is administered via subcutaneous (SC) or intradermal (ID) injection, while the anti-PD-1 antibody and chemotherapy regimens are administered via intravenous (IV) infusion.

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-20
Primary Completion
2028-09-01
Completion
2029-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07637786 on ClinicalTrials.gov